Rosuvastatin is indicated for the following cases-

• Hyperlipidemia
• Prevention of Cardiovascular diseases (myocardial infarction, stroke, angina etc.)
• Coronary heart diseases

Hyperlipidemia

Prevention of Cardiovascular diseases

Coronary Heart Disease

• Rosuvastatin is available as 5mg, 10mg, 20mg and 40mg tablets. 
• The usual starting dose is 10-20 mg. Rotuvastatin can be administered as a single dose at any time of day, with or without food.
  
• When initiating Rotuvastatin therapy or switching from another HMG-CoA reductase inhibitor therapy, the appropriate Rotuvastatin starting dose should first be utilized, and only then titrated according to the patient’s response and individualized goal of therapy.
  
• After initiation or upon titration of Rotuvastatin, lipid levels should be analyzed within 2 to 4 weeks and the dosage adjusted accordingly.
  
• The 40 mg dose of Rotuvastatin should be used only for those patients who have not achieved their LDL-C goal utilizing the 20 mg dose .

Commonly associated side effects with the use of Rotuvastatin include-

• Headache
• Myalgia
• Abdominal pain
• Asthenia
• Nausea

Headache

Myalgia

Asthenia

Nausea

• Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase with use of 40 mg dose, advanced age (≥65), hypothyroidism, renal impairment, and combination use with cyclosporine, lopinavir/ritonavir, atazanavir/ritonavir, or certain other lipid-lowering drugs. Advise patients to promptly report unexplained muscle pain, tenderness, or weakness and discontinue Rosuvastatin if signs or symptoms appear.
• Liver enzyme abnormalities and monitoring: Persistent elevations in hepatic transaminases can occur. Monitor liver enzymes before and during treatment.